Harvard Heart Letter

Heart Beat: Generic ARBs are coming

The FDA has approved the sale of a generic version of the angiotensin-receptor blocker medication losartan, and generic versions of two other ARBs may soon follow.

To continue reading this article you must be registered.

Get Licensed Content to Harvard Health

If you are interested in licensing content from Harvard Health Publications, please contact us using our online form. Our licensing and business development professionals will help you leverage consumer health content from Harvard Medical School as a clear differentiator in helping achieve your business goals.

Contact Us

Customer Log In